Related Experiment Video
Updated: Jul 18, 2026
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Alkylating benzamides with melanoma cytotoxicity: experimental chemotherapy in a mouse melanoma model
Markus Wolf1, Helmut Eskerski, Ulrike Bauder-Wüst
1Department of Radiopharmaceutical Chemistry, German Cancer Research Center (DKFZ), Heidelberg, Germany. markus.wolf@dkfz.de
Abstract:
The in-vivo antineoplastic potential of the alkylating N-(2-dialkylaminoethyl)benzamides BZA1 and BZA2, novel melanoma targeted anticancer drugs, was evaluated in a mouse melanoma model with nude mice bearing subcutaneous SkMel28, B16 or WM266-4. The maximal tolerated dose (MTD) for the intraperitoneal application of both agents was found to be 24 mg/kg. Treatment was initiated with an intraperitoneal injection of 8 mg/kg of BZA1 or BZA2 on days 0, 2 and 4 in the case of B16 melanoma on days 0, 1 and 2 after the onset of the experiment, when the mean tumor diameter ranged within 4-6 mm. The experiment was terminated when the mean tumor diameter in the control group had reached a value of 12 mm. Tumor growth delay of these agents was compared with dacarbazine (3x250 mg/kg), chlorambucil (3x5 mg/kg) and an untreated control group. Significant tumor growth delay was observed under BZA1, BZA2 and dacarbazine treatment compared with the untreated control group in all three evaluated melanomas with insignificant differences among BZA1, BZA2 and dacarbazine. The insignificant effect of chlorambucil and the strong improvement on growth delay achieved with BZA1 and BZA2 demonstrated melanoma targeting characteristics of the N-(2-dialkylaminoethyl)benzamide structure element. Dacarbazine was more effective in the in-vivo antineoplastic assay compared with the in-vitro cytotoxicity studies, probably due to hepatic bioactivation. Similar side effect intensity of BZA2 and dacarbazine was observed, whereas BZA1 was more toxic. BZA2 might represent an alternative antimelanoma drug, especially in patients not responding to dacarbazine.
Insights
Novel anticancer drugs, N-(2-dialkylaminoethyl)benzamides BZA1 and BZA2, showed significant melanoma tumor growth delay in mice. BZA2 may be a promising alternative melanoma treatment, particularly for dacarbazine-resistant cases.
Area of Science:
- Pharmacology
- Oncology
- Drug Discovery
Background:
- Melanoma remains a significant challenge in cancer treatment.
- Novel therapeutic agents are needed to improve patient outcomes.
- Alkylating agents are a class of chemotherapy drugs used to treat cancer.
Purpose of the Study:
- To evaluate the in-vivo antineoplastic potential of novel alkylating agents, BZA1 and BZA2, against melanoma.
- To compare the efficacy of BZA1 and BZA2 with established chemotherapy drugs like dacarbazine and chlorambucil.
- To assess the melanoma-targeting characteristics and toxicity profile of BZA1 and BZA2.
Main Methods:
- In-vivo evaluation in a mouse melanoma model using nude mice bearing subcutaneous SkMel28, B16, or WM266-4 melanoma cells.
- Determination of the maximal tolerated dose (MTD) for intraperitoneal administration of BZA1 and BZA2.
- Treatment regimens involved intraperitoneal injections of BZA1 or BZA2, dacarbazine, or chlorambucil, compared to an untreated control group.
- Tumor growth delay was the primary efficacy endpoint.
Main Results:
- BZA1 and BZA2 demonstrated significant tumor growth delay in all three melanoma models, comparable to dacarbazine.
- Chlorambucil showed an insignificant effect on tumor growth delay.
- The N-(2-dialkylaminoethyl)benzamide structure exhibited melanoma-targeting characteristics.
- BZA2 showed similar side effect intensity to dacarbazine, while BZA1 was more toxic.
- Dacarbazine's in-vivo efficacy exceeded its in-vitro cytotoxicity, suggesting hepatic bioactivation.
Conclusions:
- N-(2-dialkylaminoethyl)benzamides BZA1 and BZA2 are effective in delaying melanoma tumor growth in vivo.
- BZA2 shows potential as an alternative antimelanoma drug, especially for patients with dacarbazine resistance.
- Further investigation into BZA2's therapeutic potential is warranted.
